In8Bio (INAB) Net Cash Flow (2020 - 2026)
In8Bio (INAB) posted Net Cash Flow of -$5.2 million for Q1 2026, down 131.5% sequentially from $16.3 million in Q4 2025, and down 768.09% YoY from $771000.0 in Q1 2025.
In8Bio (INAB) Net Cash Flow (2020 - 2026) Analysis & Trends
In8Bio has reported Net Cash Flow for 7 years, with the latest figure at -$5.2 million in Q1 2026.
- Quarterly Net Cash Flow fell 768.09% year-over-year to -$5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 998.03% YoY) and the FY2025 annual result came in at $15.9 million, up 256.88% from the prior year.
- Net Cash Flow fell to -$5.2 million in Q1 2026 per INAB's latest filing, from $16.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $16.3 million in Q4 2025 and troughed at -$9.5 million in Q4 2022.
- A 5-year average of -$888882.4 and a median of -$2.8 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2026: Net Cash Flow jumped 196.37% in 2023, then sank 768.09% in 2026.
- Over 5 years, Net Cash Flow stood at -$9.5 million in 2022, then jumped by 189.06% to $8.4 million in 2023, then dropped by 15.47% to $7.1 million in 2024, then soared by 129.44% to $16.3 million in 2025, then tumbled by 131.5% to -$5.2 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$5.2 million, $16.3 million, and -$2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 225.59 Mn |
| 10 | In8Bio | 23.75 Mn | 23.75 Mn | - | -4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.03 Mn |
| Jun 30, 2026 | -4.03 Mn |
| Mar 31, 2026 | -5.15 Mn |
| Mar 31, 2026 | -5.15 Mn |
| Dec 31, 2025 | 16.35 Mn |
| Dec 31, 2025 | 16.35 Mn |
| Sep 30, 2025 | -2.54 Mn |
| Sep 30, 2025 | -2.54 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | 771,000.00 |
| Mar 31, 2025 | 771,000.00 |
| Dec 31, 2024 | 7.13 Mn |
| Dec 31, 2024 | 7.13 Mn |
| Sep 30, 2024 | -6.22 Mn |
| Sep 30, 2024 | -6.22 Mn |
| Jun 30, 2024 | -2.80 Mn |
| Jun 30, 2024 | -2.80 Mn |
| Mar 31, 2024 | -8.27 Mn |
| Mar 31, 2024 | -8.27 Mn |